Back to Search
Start Over
Research Progress in the Efficacy and Safety of ALK Inhibitors in the Treatment of NSCLC Brain Metastasis
- Source :
- Chinese Journal of Lung Cancer, Vol 26, Iss 5, Pp 400-406 (2023)
- Publication Year :
- 2023
- Publisher :
- Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2023.
-
Abstract
- Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases harbor anaplastic lymphoma kinase (ALK) fusion. ALK-positive NSCLC patients have shown significant therapeutic benefits after treatment with ALK inhibitors. Over the past decade, ALK inhibitors have rapidly evolved and now exist in three generations: first-generation drugs such as Crizotinib; second-generation drugs including Alectinib, Brigatinib, Ceritinib, and Ensartinib; and third-generation drugs like Lorlatinib. These drugs have exhibited varying efficacy in treating brain metastases in ALK-positive NSCLC patients. However, the numerous options available for ALK inhibition present a challenge for clinical decision-making. Therefore, this review aims to provide clinical guidance by summarizing the efficacy and safety of ALK inhibitors in treating NSCLC brain metastases.
Details
- Language :
- Chinese
- ISSN :
- 10093419 and 19996187
- Volume :
- 26
- Issue :
- 5
- Database :
- Directory of Open Access Journals
- Journal :
- Chinese Journal of Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8e0e3eba503d4a8186f70efa0b4919f6
- Document Type :
- article
- Full Text :
- https://doi.org/10.3779/j.issn.1009-3419.2023.101.10